The U.S. Food and Drug Administration approved Duavee (conjugated estrogens/bazedoxifene). It is a prescription medicine that is used after menopause for women with a uterus to reduce moderate to severe hot flushes and help reduce chances of developing osteoporosis. Duavee is marketed by Wyeth Pharmaceuticals, Inc. (a subsidiary of Pfizer Inc.,) based in Philadelphia, Pa. See http://www.drugs.com/newdrugs/fda-approves-duavee-hot-flashes-prevent-osteoporosis-3922.html for more information
No comments:
Post a Comment